← Leaderboards
Gregory A. Storch
Washington University
$7,078,189
Attributed
$7,292,323
Total exposure
11
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $954.4K · FY2005–23$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$7,292,323 · 11
By mechanism
R01$3,235,857 · 1
T32$1,421,909 · 2
UH2$1,381,843 · 1
R21$860,404 · 2
U54$379,279 · 1
M01$13,031 · 4
Top collaborators
- Thomas W Ferkol2 shared
Most similar at Washington University
Same institution · by research overlap
- Kristine M. Wylie$7,245,177
- Juliane Bubeck Wardenburg$13,099,316
- Scott J Hultgren$48,876,558
- Carl Frieden$6,868,735
- Stephanie Ann Fritz$8,750,405
Others in their field
Top investigators on “Viral”
- Lawrence Corey · Fred Hutchinson Cancer Center$466,994,927
- David Heimbrook · Leidos Biomedical Research, Inc.$366,090,791
- Daniel R Kuritzkes · Brigham And Women'S Hospital$267,074,199
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$252,763,614
- Judith S. Currier · University Of California Los Angeles$185,434,785
- Constance Ann Benson · University Of California, San Diego$165,517,633
Research focus
ViralBaseAcuteVirusVirus DiseasesSamplingWashingtonUniversitiesChildBlood SpecimenCommunicable DiseasesChildhoodImmunologyFeverMolecularInvestigationEnrollmentAids/Hiv ProblemGenomeHematopoietic Stem CellsOrganismOrgan TransplantationImmune SystemNatural Immunosuppression
Grant awards (29)
Characterizing respiratory exacerbations in primary ciliary dyskinesia$231,393
R21 · FY2023 · TR
Characterizing respiratory exacerbations in primary ciliary dyskinesia$196,875
R21 · FY2022 · TR
New test for the diagnosis of acute respiratory infection that detects viruses and evaluates host gene expression in a nasal sample$196,823
R21 · FY2020 · AI · contact PI
New test for the diagnosis of acute respiratory infection that detects viruses and evaluates host gene expression in a nasal sample$235,313
R21 · FY2019 · AI · contact PI
Pediatric Infectious Diseases and Immunity Training Program$153,547
T32 · FY2018 · AI · contact PI
Pediatric Infectious Diseases and Immunity Training Program$137,620
T32 · FY2017 · AI · contact PI
DEFINING THE HUMAN VIROME IN IMMUNOCOMPROMISED CHILDREN$646,293
R01 · FY2016 · AI · contact PI
Pediatric Infectious Diseases and Immunity Training Program$135,853
T32 · FY2016 · AI · contact PI
DEFINING THE HUMAN VIROME IN IMMUNOCOMPROMISED CHILDREN$643,980
R01 · FY2015 · AI · contact PI
Pediatric Infectious Diseases and Immunity Training Program$151,205
T32 · FY2015 · AI · contact PI
DEFINING THE HUMAN VIROME IN IMMUNOCOMPROMISED CHILDREN$647,489
R01 · FY2014 · AI · contact PI
Pediatric Infectious Diseases and Immunity Training Program$144,608
T32 · FY2014 · AI · contact PI
DEFINING THE HUMAN VIROME IN IMMUNOCOMPROMISED CHILDREN$629,648
R01 · FY2013 · AI · contact PI
DEFINING THE HUMAN VIROME IN IMMUNOCOMPROMISED CHILDREN$668,447
R01 · FY2012 · AI · contact PI
THE HUMAN VIROME IN CHILDREN AND ITS RELATIONSHIP TO FEBRILE ILLNESS$250,000
UH2 · FY2010 · AI · contact PI
THE HUMAN VIROME IN CHILDREN AND ITS RELATIONSHIP TO FEBRILE ILLNESS$177,458
UH2 · FY2010 · AI · contact PI
THE HUMAN VIROME IN CHILDREN AND ITS RELATIONSHIP TO FEBRILE ILLNESS$954,385
UH2 · FY2009 · AI · contact PI
Virology and Smallpox Vaccinations$379,279
U54 · FY2008 · AI · contact PI
Mechanisms of Childhood Infection and Immunity$231,240
T32 · FY2007 · HD · contact PI
PHASE III EVALUATION FOLLOWING NEONATAL HSV INFECTIONS INVOLVING THE CNS$271
M01 · FY2007 · RR · contact PI
PHASE III EVALUATION FOLLOWING NEONATAL HSV LIMITED TO THE SKIN, EYE AND MOUTH$136
M01 · FY2007 · RR · contact PI
Mechanisms of Childhood Infection and Immunity$233,918
T32 · FY2006 · HD · contact PI
PHASE III EVALUATION FOLLOWING NEONATAL HSV INFECTIONS INVOLVING THE CNS$1,666
M01 · FY2006 · RR · contact PI
PHASE III EVALUATION FOLLOWING NEONATAL HSV LIMITED TO THE SKIN, EYE AND MOUTH$416
M01 · FY2006 · RR · contact PI
Mechanisms of Childhood Infection and Immunity$233,918
T32 · FY2005 · HD
PHASE III EVALUATION FOLLOWING NEONATAL HSV LIMITED TO THE SKIN, EYE AND MOUTH$6,572
M01 · FY2005 · RR
PHASE III EVALUATION FOLLOWING NEONATAL HSV INFECTIONS INVOLVING THE CNS$2,054
M01 · FY2005 · RR
Phase III Evaluation Following Neonatal HSV Limited to the Skin, Eye and Mouth$958
M01 · FY2004 · RR
Phase III Evaluation Following Neonatal HSV Infections Involving the CNS$958
M01 · FY2004 · RR